Abstract:Glioblastoma (GBM) is the most common type of malignant tumor of the central nervous system. The prognosis of patients with GBM is very poor, with a survival time of ~15 months. GBM is highly heterogeneous and highly aggressive. Surgical removal of intracranial tumors does provide a good advantage for patients as there is a high rate of recurrence. The understanding of this type of cancer needs to be strengthened, and the aim of the present study was to identify gene signatures present in GBM and uncover their potential mechanisms. The gene expression profiles of GSE15824 and GSE51062 were downloaded from the Gene Expression Omnibus database. Normalization of the data from primary GBM samples and normal samples in the two databases was conducted using R software. Then, joint analysis of the data was performed. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed, and the protein‑protein interaction (PPI) network of the differentially expressed genes (DEGs) was constructed using Cytoscape software. Identification of prognostic biomarkers was conducted using UALCAN. In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes. The top 1,000 upregulated DEGs and all of the downregulated DEGs were selected for GO, KEGG and prognostic biomarker analyses. The GO results showed that the upregulated DEGs were significantly enriched in biological processes (BP), including immune response, cell division and cell proliferation, and the downregulated DEGs were also significantly enriched in BP, including cell growth, intracellular signal transduction and signal transduction by protein phosphorylation. KEGG pathway analysis showed that the upregulated DEGs were enriched in circadian entrainment, cytokine‑cytokine receptor interaction and maturity onset diabetes of the young, while the downregulated DEGs were enriched in the TGF‑β signaling pathway, MAPK signaling pathway and pathways in cancer. All of the downregulated genes and the top 1,000 upregulated genes were selected to establish the PPI network, and the sub‑networks revealed that these genes were involved in significant pathways, including olfactory transduction, neuroactive ligand‑receptor interaction and viral carcinogenesis. In total, seven genes were identified as good prognostic biomarkers. In conclusion, the identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future.

Identification of candidate biomarkers for GBM based on WGCNA

Identification and Validation of SNHG Gene Signature to Predict Malignant Behaviors and Therapeutic Responses in Glioblastoma

Candidate Biomarkers and Molecular Mechanism Investigation for Glioblastoma Multiforme Utilizing WGCNA.

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Identification of Survival‑associated Key Genes and Long Non‑coding RNAs in Glioblastoma Multiforme by Weighted Gene Co‑expression Network Analysis.

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Bioinformatics Analysis of High-Throughput Data to Validate Potential Novel Biomarkers and Small Molecule Drugs for Glioblastoma Multiforme

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Identification of Biomarkers for the Transition from Low-Grade Glioma to Secondary Glioblastoma by an Integrated Bioinformatic Analysis.

Genome-wide Expression Profiling of Glioblastoma Using a Large Combined Cohort.

Bioinformatics Analysis and Experimental Validation for Exploring Key Molecular Markers for Glioblastoma

Identification of Key Candidate Genes and Pathways in Glioblastoma by Integrated Bioinformatical Analysis

Identification of Glioblastoma Gene Prognosis Modules Based on Weighted Gene Co-Expression Network Analysis

Predicting Glioblastoma Prognosis Networks Using Weighted Gene Co-Expression Network Analysis on TCGA Data

Identification of a Specific Gene Module for Predicting Prognosis in Glioblastoma Patients

Identification of biomarkers and ceRNA network in glioblastoma through bioinformatic analysis and evaluation of potential prognostic values

Identification of Key Genes Involved in the Recurrence of Glioblastoma Multiforme Using Weighted Gene Co-Expression Network Analysis and Differential Expression Analysis.

Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma

Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma

Systematic analysis of the long noncoding RNA (lncRNA)-miRNA-mRNA competing endogenous RNA network to identify prognostic biomarkers and the potential regulatory axis in glioblastoma multiforme